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ABSTRACT
Background: To reduce the reliance on clinical judgment for the regulation of sports-related
traumatic brain injury, identifying and measuring objective to biofluid biomarkers can provide
important insight into the diagnosis (Determining the type and origin of a disorder) and prognosis
(Determining the chance of survival of a disorder) of SR-TBIs. A biomarker is a qualitative or
quantitative measurement that provides a measure of a subject’s physiological or pathological
condition at a specific time or during a disease state. Recent literature has suggested that
biomarkers can help in the screening of patients exhibiting symptoms of mild traumatic brain
injury (mTBI). Despite insights from recent research, it is not clear whether biomarkers and
assessments of sports-related TBI are well-aligned. The objective of this study sought to review
the current literature on predictive values of biomarkers: glial fibrillary acidic protein (GFAP),
calcium channel binding protein S100 subunit beta (S100β), total-tau and neuron-specific enolase
(NSE) for sports-related Traumatic Brain Injuries (SR-TBIs) to improve comprehension of
biological and clinical contexts that can help evaluate the use of these biomarkers in sports-related
TBIs and their potential function.
Methods: The study was reported based on guidelines recommended by the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA: 2020 Edition) of 8 studies related to
the assessment of biomarkers concerning SR-TBI. Literature searches were carried out on
PubMed, Google Scholar, ScienceDirect, and ResearchGate. With an evidentiary table, the
characteristics of the studies included in the meta-analysis (n = 14 studies) were presented. A
significant role for biomarkers in the management of mild traumatic brain injury is suggested by
the results of this analysis. From the literature, the significance of biomarkers in SR-TBI was
identified along with the biomarkers that can facilitate more accurate clinical decision-making.
ii

Results: The initial search resulted in 73 articles, and the application of exclusion criteria and
removal of duplicates resulted in the inclusion of 14 articles. Eight of the included studies were
([26], [27], [28], [30], [34], [39], [40], [41]), three were cohort studies ([25], [37], [45]) one was a
pilot study [32], one interview, and an observational study [44]. The review was carried out to
determine the efficacy of Biomarkers GFAP, S100β, Total-tau, and NSE to help in the screening
of mild traumatic brain injury (mTBI) in patients showing symptoms. The focus is on athletes
presenting at an emergency department with possible mTBI requiring a CT scan based on the
application of a clinical algorithm. A forest plot was utilized, and the studies had low heterogeneity
or variability (P<0.23) and I2 statistic is equal to 26%. A random-effects model was used. The plot
shows the odds ratio favoring the control group thus depicting the negative predictive value of the
biomarkers such that in the control group no mTBI case was reported. The biomarkers were only
present in the experimental group which had cases of mTBI. A funnel plot was also used to
determine negative predictive values and to provide data screening for the distribution of 14
studies, resulting in a lower quadrant precision overall.
Conclusions: It was established that the utility of biofluid biomarkers in the prediction of mild
traumatic brain injury due to SRC is significant when the markers are used in large combinations.
The four biofluid biomarkers (S100β, total-tau, GFAP, NSE) under study have strong predictive
ability for mTBI, and their use can reduce the number of CT scans among TBI patients
participating in athletic activities. Although preliminary evidence shows that other diagnostic
treatments may help to mitigate traumatic brain injury sequelae, clinical trials are needed to further
test their efficacy, specifically with diverse and high-risk populations. Luckily, the research on
mTBI biomarkers is rapidly advancing, and should these biomarkers be better established
clinically, they could easily hold many important roles.
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INTRODUCTION
When engaging in sporting activities, most athletes tend to engage in physical touch, which may
sometimes expose them to the risk of getting an internal brain injury commonly known as
Traumatic Brain Injury (TBI). A traumatic brain injury, or concussion, results from a drastic
external blow to the head that can be diagnosed through evidence of alterations in brain function
and/or behavioral patterns. [1] Concussions will result from exposing the head to significant
impacts that may result in the change of position of the brain in the skull, causing a rupture of
blood vessels and injury of several cells present in the brain. [2] A TBI will pathologically develop
from primary and secondary injuries which will lead to brain injury. The primary injury is related
to the first onset of external impact on the skull resulting in the shaking of the skull. The secondary
injury will occur minutes or days following the primary injury and can result in both physical
and/or chemical changes inside the brain. [3] This secondary injury in the pathophysiology of a
TBI is what brings about the concern for possible behavioral change post-injury. Traumatic brain
injury (TBI) continues to progressively become more of a public health concern worldwide.
According to the CDC, between the years 2001 and 2010, deaths and visits to the hospital
drastically increased in cases related to brain trauma injuries. [3] Specifically, males in contact
sports, such as football, soccer, and ice hockey, are at a higher risk of being diagnosed with a TBI,
and adolescents and young adults had the highest incidence of a sports-related TBI. [4]
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Current literature indicates that the impacts of a TBI may go beyond physical, affecting mental
health. [5] Recent studies have identified that athletes who suffer a concussion will exhibit
significant behavioral changes. [5] According to a study, high school and college athletes who
suffered and were diagnosed with concussions developed depressive symptoms, confusion, and
mood changes within three weeks following the diagnosis. [6] A study found that, in an older
population, social behavior and etiquette were worse after a TBI diagnosis than before. [7] One
study notes that the negative social impacts of a TBI perhaps are exacerbated within children, also
affecting family dynamics, academic performance, and athletics. [8] Collectively, these studies
indicate that TBIs can alter behavior in athletes in general. Athletes who participate in high-contact
sports such as football, soccer, and ice hockey are more likely to suffer a traumatic brain injury.
[9] Damaging consequences that follow a TBI within these sports can be short-term or long-term
depending on some important factors such as the severity of the TBI. [10] Therefore, in
anticipation of addressing these concerns in the literature surrounding this consequential topic, this
study will examine biomarkers in sports-related TBIs to determine if these biological measures are
significant enough to possibly prevent such consequences.

Short-term Consequences
Short-term complications in a sports-related traumatic brain injury (SR-TBI) can occur
immediately after the injury. The signs and symptoms of short-term complications can depend on
factors, such as TBI severity and/or physical characteristics of the injury. [11] These factors can
help categorize the degree of the following types of TBIs: Mild traumatic brain injury (mTBI) and
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Moderate to severe traumatic injury. Temporarily, traumatic brain injuries may damage your brain
cells, but a more serious traumatic brain injury can result in damage to the brain such as bleeding
and bruising. Normally, patients who suffer from mild traumatic brain injuries (mTBI) can show
physical, sensory, and/or cognitive symptoms. [10] Physical symptoms of a mTBI include but are
not limited to headaches, nausea, dizziness, and more. [10] Sensory symptoms that can be observed
in a person after a mTBI are light-sensitive, while cognitive/behavior symptoms can be observed
as abrupt changes in mood or the possible feeling of anxiety or depression. [10] Patients dealing
with untreated moderate to severe TBI can show the following physical symptoms: loss of
consciousness or coordination, or even possible seizures. Cognitive or mental symptoms in
moderate to severe TBIs can cause agitation or other unusual behavior in the patient. [11]

Long-term Consequences
Untreated brain injuries can lead to several complications immediately after the incident. The
severity of an injury following a traumatic brain injury can also increase the risk of more serious
complications. [12] A prolonged injury to the brain that is moderate to severe can cause a persistent
change in a person's consciousness, awareness, and responsiveness. There are dangerous levels of
consciousness, including but not limited to comas and/or a vegetative state. A coma results in
complete unawareness and the person does not respond to a stimulus. Vegetative states indicate
extensive brain damage resulting in the unawareness of surroundings, but the person may respond
to partial stimulation. [13]

Chronic traumatic encephalopathy (CTE) is a progressive neuropsychological condition caused by
repeated force to the head. Athletes who play high collision sports are at a higher risk of developing
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CTE compared to nonphysical sports. [10] Cognitive or behavioral changes that occur years after
a concussion are known as CTE. [14] CTE has been linked with the following high collision sports:
football, hockey, soccer, and others. [14] Particularly in sports, early diagnosis is critical to prevent
CTE and long-term consequences. [14] Signs and symptoms can delay coming forward after a
person has sustained a brain injury. To provide optimal care to athletes suffering from CTE, which
is thought to be primarily caused by repetitive head trauma, early detection methods are
fundamental. [14] In addition to headaches, dizziness, unsteadiness in walking, and fatigue,
patients with CTE may suffer from cognitive and psychosocial symptoms.

Biomarkers in traumatic brain injury
A biomarker can be detected in bodily fluids or tissues and is referred to as a biological molecule
or substance that can be examined to predict the incidence or outcome of a disease. Understanding
the relationship between quantifiable biological processes and clinical consequences is critical for
expanding mTBI therapy options. On the contrary, many of the more well-studied biomarkers are
susceptible to deterioration. Biomarkers are currently only used in clinical practice to rule out the
need for a CT scan. However, an exciting and growing area of research focuses on blood tests for
TBI diagnosis. A blood test approved by the FDA in 2018 detects two proteins released into the
bloodstream by the brain following a mild concussion, UCH-L1, and GFAP. [23] After brain
injury, proteins would be synthesized and secreted from neurological cells into the CSF, where
they can possibly cross the blood-brain barrier (BBB) and enter the peripheral circulation. [15]
The neuron-specific enolase (NSE) and the ubiquitin C-terminal hydrolase (UCH-L1) are both
neuron-derived proteins, while protein S100 Beta (S100β) and glial fibrillary acidic protein
(GFAP) are both glial-derived proteins. Over the past decade, a growing body of research has
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supported the use of biomarkers to detect concussions in children and adults. [16] Over a dozen
studies have measured different biomarkers including Protein S100 Beta (S100β), glial fibrillary
acidic protein (GFAP), and neuron-specific enolase (NSE). [12] Protein S100 Beta (S100β) and
glial fibrillary acidic protein (GFAP) have been the most helpful thus far in the growing body of
research supporting biomarkers in patients with TBI. [12] Biomarkers may be the best way for
athletes to prevent further injuries if they receive early and personalized treatment after suffering
a concussion. Those who are trained in sports medicine, such as athletic trainers, coaches, and
clinicians, could detect concussions with a point-of-care test, for instance. Clinically, it can be used
to determine whether a patient has suffered a concussion and to screen them for neuroimaging
such as CT or MRI. The incorporation of biomarkers into guidelines for returning to sports could
be crucial to monitoring injury development and improvement in athletes at high risk of repeated
injuries. In the evaluation of new treatments and therapies for concussion, biomarkers could even
serve as surrogate measures of efficacy. [16] In sports such as football, ice hockey, and soccer,
where concussions are common, early diagnosis and predictive tools are becoming increasingly
important to prevent CTE and other long-term effects of concussions.

It is possible that diagnostic testing and a comprehensive medical evaluation may reveal the issues
following a TBI injury, but the entirety of the injury may not be completely understood
immediately after. Diagnosis of a TBI is individualized, depending on many factors such as age,
health, medical history, the extent of the condition, and the presence of other injuries. [22]
Currently, healthcare providers utilize different tests and measures to diagnose TBI such as the
Glasgow coma scale (GSC), blood tests, and others. Although imaging can be found to be accurate,
it is possible that false positives can occur and that flaws can be evident. Also, patients are exposed
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to more radiation utilizing these current imaging techniques. In some cases, a biomarker blood test
can possibly eliminate the need for a CT scan on individuals whose injury is unlikely to show up
on the scan.

Computed tomography (CT) and Magnetic resonance imaging (MRI) are imaging brain tests,
which have been identified to be the most efficient way currently of observing the condition of
internal body parts. [22] The functions of these tests specifically include imaging techniques to
diagnose brain injuries such as a TBI in the brain. [23] Specific to traumatic brain injuries, the
most common technology used to determine patients with a more severe TBI is a CT. [22] As a
diagnostic tool, it uses X-rays, which are electromagnetic waves that create an image of soft tissues
and bones to help determine where brain damage occurred. [24] An MRI can be used to identify
changes in the performance and structure of the brain after an injury, as well as assess the structure
of the brain at a more detailed level. [22] After initial treatment and assessment, an MRI may be
used. Since the test is more sensitive, it can detect the slightest of changes in the brain that can be
missed on a CT scan. [22,24] Much of what occurs to the brain following a TBI occurs at the
cellular level, so brain scans can be utilized to determine the magnitude of the brain injury and
whether surgery is required to repair any damage. [22] The Glasgow Coma Scale is one of the
most widely used tools for assessing the level of consciousness after TBI. [23] This method is
commonly a 15-point, standardized test that assesses verbal abilities, eye functions, and physical
awareness of body movements. There are also numerous in-depth tests such as cognitive or
speech/language tests that can identify levels of injury or damage in TBI patients, in addition to
neurological exams, which are a series of quick questions and exercises that assess how well the
brain and body are functioning after a TBI. [22] As part of a neurological exam, you can assess
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abilities such as but not limited to the patient's motor skills, senses, coordination, emotions, and
changes in behavior. For medical evaluation, screening tools can identify the most concerning
concussions. [24]

Currently, diagnosis of TBIs relies on neurological examination, use of Computerized tomography
(CT), X-rays, patient history, and presenting symptoms. [35] The difficulty arises in the fact that
symptoms of mTBIs can present themselves despite a negative neuroimaging result and that
diagnosis can be subjective when based on self-reported neurological symptoms. [33] The
diagnosis of mTBIs is also made difficult due to the quick resolution of symptoms and the lack of
objective evidence for a positive diagnosis using neuroimaging techniques. [33] Accurate
diagnosis can also be impeded by the desire to conceal signs or the inability of the patient to
identify subtle changes in consciousness and other dysfunctions. [33] The tendency to conceal
symptoms is often motivated by an athlete and/or coach’s desire for a return to play. [42] A
premature return to play, however, can be unsafe for the athlete due to their increased risk of
developing pronounced neurological injuries if not fully recovered. [42] Thus, there is a necessity
for objective indicators of traumatic brain injury.

Neuroimaging techniques can potentially be unavailable because of patient radiation exposure and
their high-cost healthcare expenditures compared to the sparse distribution of subjects across
regions. The need to attend to patients with possible mTBI in an efficient and economically
effective manner has led to significant research and development in accurate biofluid biomarkers.
Designations of biomarkers connected to TBI pathophysiology are of clinical value due to their
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potential for increased accuracy in the characterization and risk analysis of TBI. Personalized and
targeted therapeutic interventions can be made possible as a result.

This meta-analysis aims to review the available literature on the predictive value of biofluid
biomarkers for concussions and to emphasize the biological and clinical contexts that can help
evaluate the use of these biofluid biomarkers in efficiently diagnosing and treating SR-TBIs. This
meta-analysis concerned itself with biomarkers that hold promising value in diagnosing TBIs
within the clinical setting. These biomarkers include S100 calcium-binding protein B (S100β) and
glial fibrillary acidic protein (GFAP).

8

METHODOLOGY
Overview
A comprehensive review was conducted to evaluate the predictive value of biofluid biomarkers
for concussions to improve comprehension of biological and clinical contexts that can help
evaluate the use of these biofluid biomarkers in sports related TBIs. This review was conducted
concurrently from January 2022 to March 2022. The methodology for this meta-analysis literature
review is in accordance with the PRISMA 2020 statement guidelines [47].

Eligibility Criteria
This research paper was reported based on the 2020 Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) edition. Literature searches were carried out on PubMed,
Google Scholar, ScienceDirect, and ResearchGate databases. A second search was performed on
the reference lists of the studies obtained in the initial search. Similar articles recommended by the
digital libraries mentioned above were included in the results of the second literature search. The
search included studies on the utility of S100 calcium-binding protein B (S100β), glial fibrillary
acidic protein (GFAP), neuron-specific enolase (NSE), and tau in the prediction of mild traumatic
brain injury. Only the results of the first five pages were included to ensure the relevance of the
articles to this meta-analysis was assured to some degree. This was also done to ensure the most
recently published and most cited articles were obtained in the initial search. Search results were
limited to articles published from 2000 to 2021.
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Information Sources
A meta-analysis literature search began in January 2021 using the following electronic databases:
PubMed (2000-2020), Google Scholar (2000-2020), ScienceDirect (2000-2020), and
ResearchGate databases. All databases were last searched in March 2022.

Search Strategy
Keywords used in the search included "concussion," "sport-related concussion (SRC) ", "clinical
studies", "predictive value", " biofluid biomarkers", or "NSE " or "GFAP " or " S100β." After the
initial search and assessment of the results, new keywords were added, such as “mild traumatic
brain injury," " mTBI," and “TBI pathophysiology." The keywords were used in different
combinations to guide the literature search and ensure the relevance of the articles in the search
results.

Selection Process
An initial screening of articles to remove duplicates and assess inclusion/exclusion criteria by title
and abstract was conducted independently. Full-text analysis was then conducted to determine the
eligibility of the remaining studies. Reference lists of all eligible articles were then reviewed and
screened for additional articles. All eligible studies were included in the meta-analysis review (see
Figure 1).
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Figure 1: Flow chart of the Meta-Analysis review search selection process

Guidelines and Selection Criteria
In this meta-analysis, studies that focused on biofluid biomarkers for concussion and that described
the biological and clinical contexts that could help evaluate the use of these biofluid biomarkers in
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SR-TBI were included. Studies that were only done on adults, that is, participants who are 18 years
and older, diagnosed with a concussion were included. Studies that examine biofluid biomarkers
S100 calcium-binding protein B (S100β), glial fibrillary acidic protein (GFAP), neuron-specific
enolase (NSE), and tau in the prediction of mild traumatic brain injury in sports were included.

The titles of the articles obtained in the initial search were analyzed to determine that they covered
the subject of study of this research paper. The abstracts of the remaining articles were then studied
to establish the relevance of the given articles to the current study, such that they tried to answer
the questions posed herein. At this point, the articles that passed the described eligibility criteria
were then fully read to determine their utility and significance in achieving the goal of metaanalysis. The exclusion criteria included the similarity of studies obtained and the evidence of a
clearly defined study objective mentioning the predictive value of biofluid biomarkers for
concussion. Studies that focused on health and social care staff were not included. Review articles,
case reports of fewer than 5 participants, commentaries, studies that examine participants with
conditions that can be confounders, and studies involving the use of medication were excluded.
Studies that were not reported in English were not included. Articles with individual keywords
were excluded as most of them did not contain information relevant to this research paper.

Data Collection
The data was collected from the selected studies to establish a suitable answer to the questions of
this research paper. The data from the studies that passed the exclusion and inclusion criteria were
extracted into a predefined extraction table. The author's name, publication date, type of study,
sample size, demographics, and the studies' results were recorded. The extraction table provided a
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means of assessing the reliability of the included papers according to the parameters described
below. Review Manager 5.4 (RevMan) is Cochrane's software that facilitates the preparation of
study data. Within this meta-analysis, a forest plot and funnel plot were designed and created using
RevMan version 5.4.
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RESULTS
Study Selection
For the literature review, the initial search of electronic databases resulted in 73 studies, and the
application of exclusion criteria by title and abstract and removal of duplicates resulted in the
inclusion of 14 studies. A 2020 PRISMA diagram detailing the process of eligible article selection
was included in this meta-analysis and can be found in Figure 1.

Study Characteristics
Table 3 illustrates the characteristics of the included studies. Information of characteristics
including author, type of study/research design, biomarker protein analyzed, number of
participants in the study, sampling type-assay analyzer, results/conclusions/recommendations of
the studies, the mean age of participants, biomarker levels in TBI patients, and biomarker levels
in controls. Eight of the included studies were ([26], [27], [28], [30], [34], [39], [40], [41]), three
were cohort studies ([25], [37], [45]) one was a pilot study [32], one interview, and an
observational study [44]. The studies essentially represented the current body of knowledge
concerning the prediction of mild traumatic brain injury using biomarkers. Regarding the assays
used among the 14 studies evaluated, 4 used electrochemiluminescence immunoassay (ECLIA) on
an Elecsys analyzer or the Cobas 6000 analyzer (Roche Diagnostics), 1 used venipuncture
(Fujirebio Diagnostics), 1 used Human Neurology 4-Plex A assay (N4PA) on an HD-1 Single
molecule array, 2 used immunoluminometric assays, 3 used immunosorbent assays(ELISA), and
1 used serum digital array technology, 1 used sandwich chemiluminescence immunoassay
(LIAISON®), 1 used immunoradiometric assay kit (Sangtec®).
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Table 1: Reference table for peak levels and characteristics of investigated biomarkers

Biomarker
S100β
GFAP
NSE
tau-T

Peak Levels after mTBI
1-3 hours
About 24 hours
About 12 hours
About 1 hour

Cell
astrocyte
astrocyte
neuron
neuronal axon

Mechanism
astrogliosis
glial damage
neuronal damage
axonal injury

Table 1 represents the characteristics of the 4 investigated biomarkers: S100β, GFAP, NSE, and
tau-T. Properties of these biomarkers included in the reference table are peak levels after a mTBI,
the type of cell that expresses that biomarker, and the mechanism of causation.

Table 2: Studies Indicating Clinical Utility of Investigated Biomarkers

Table 2 shows which studies indicate the clinical utility of the investigated biomarkers.
Demonstrating a correlation between the 14 studies included in this review and the four
investigated biomarkers: s100β, NSE, GFAP, and T-tau.
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Table 3: Evidence table summarizing studies assessing biomarkers in athletes

Author Type of BM
study/
Protein
Researc analyzed
h Design
(BlaisL’Écu
yer et
al.,
2020)

Cohort
studyQuantita
tive
analysis

S100β
serum
protein

# Of
Participant
sExperime
nt/Control
476/N/A

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Serum
(Venous)
-enzymelinked
immunos
orbent
assay
(ELISA)

S100β median value was for
41 ±
patients with clinically
18
important brain injury versus
the median for patients without
clinically important brain
injury.
Twenty-four (5.0%) patients
had a clinically significant
intracranial hemorrhage while
37 (7.8%) patients had any
type of intracranial bleeding.
Sensitivity and specificity of
the S100β protein level, if used
alone to detect clinically
important brain injury, were
16.7% (95% CI 4.7-37.4)
88.5% (95% CI 85.2-91.3),
respectively.
S100β serum protein level was
not associated with clinically
significant intracranial
hemorrhage in mTBI patients.
This protein did not appear to
be useful to reduce the number
of CTs prescribed in the ED
and would have missed many
clinically important brain
injuries.
Future research should focus
on different ways to assess
mTBI patients and ultimately
reduce unnecessary head CT.
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Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

S100β
Median:
0.043
μg/L
Range:
0.0080.080

S100β
Median:
0.039 μg/L
Range:
0.0230.059

Author Type of BM
study/
Protein
Researc analyzed
h Design

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

(Schul
te et
al.,
2015)

Venipunc
tures(Fujirebi
o
Diagnosti
cs, Inc.,
Göteborg
, Sweden

For S100β, 50 % had follow-up 21
testing results lower than the
post-injury result.
For NSE, 92 % of NSE followup results were lower than
post-injury.

(Bogo
slovsk
y et
al.,
2017)

Clinical
studyQuantita
tive
analysis

Clinical
trialQuantita
tive
analysis

# Of
Participant
sExperime
nt/Control
NSE and 127/N/A
S100β
enzyme

tau,
GFAP,
and
Ab42

34/69

Mean
age of
partici
pants

100% of the results for S100β
and NSE were within the
athlete-derived reference
intervals upon return-to-play
and season end.

The reported workflow
provides a framework for the
eventual implementation of
biomarkers for concussion
assessment into existing
assessment protocols and
strengthens the need for
reliance on clinical laboratory
testing. Athlete-specific
reference intervals will be
required to adequately interpret
results.
Serum
Plasma levels of GFAP, tau,
39
(Venous) and Ab42 are all increased up
- Digital
to 90 days after TBI compared
array
with controls.
technolog The levels are maximal on Day
y
0 for GFAP and tau and on
(Quanteri Day 30 for Ab42.
x
Corporati Total tau levels: Day 30
on,
correlated with clinical and
Lexingto radiological variables of TBI
n, MA)
severity.
Ab42 plasma levels:
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BM levels
in TBI
patients

BM levels
in controls

NSE
NSE
Range: 6.7 Range: 3.7
to 23.9
to 8.9 μg/L
μg/L
S100β
S100β
Range: 0 to
Range: 32 96 ng/L
to 250
ng/L

Total
panel
levels:
1.350
pg/mL
Range:
0.8870–
2.280

0.80
pg/mL
Range:
0.8–1.070

Author Type of BM
study/
Protein
Researc analyzed
h Design

# Of
Participant
sExperime
nt/Control

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

31.5 ±
13.3

S100β
Range:
13.2 ±
22.2

N/A

Day 30 correlated with clinical
outcome.

(HER
RMA
NN et
al.,
2000)

(Papa
et al.,
2014)

Clinical
studyQuantita
tive
analysis

Prospect
ive
Cohort
StudyQuantita
tive
analysis

NSE and 66
S100β

GFAP
and
S100β

208/109

Venous
blood
samplesimmunol
uminome
tric
assays
(Sangtec
®) and a
fully
automate
d LIAmat®
system

A combination of all three
biomarkers on Days 0 and 30
can be used to differentiate
controls from mTBI
populations and may be useful
as biomarkers of TBI in both
acute and subacute phases.
The significant positive
correlation between S100β and
NSE concentrations and
volume of contusions as
demonstrated in the present
indicates that increased levels
of both proteins must be
attributed to brain injury.

Data indicates that early
release patterns of NSE and
S100β may reflect the
pathophysiological
consequences of traumatic
brain injury and may
mirror complex neuronal-glial
interactions
Blood
In a general trauma population
samples- with and without mTBI, GFAP
sandwich out-performed S100β in
enzyme- detecting traumatic intracranial
linked
CT lesions, particularly in the
immunos setting of extracranial lesions
orbent
on head CT and fractures to
assays
the torso and extremities.
(ELISAs) Both GFAP and S100β
demonstrated a rapid
appearance in serum postinjury with levels detectable
within an hour of injury. The
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NSE
Range:
328.0 ±
261.1

40

GFAP
cutoff
level of
0.067
ng/mL
S100β
cutoff
level of
0.020
ng/mL

N/A

Author Type of BM
study/
Protein
Researc analyzed
h Design

# Of
Participant
sExperime
nt/Control

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

35

GFAP and
S100β
were
lower in
ICP
of 25 than
ICP of 25
mm H2O
(p 0.0005)

N/A

temporal profile of GFAP and
S100β differed slightly.

(Pelin
ka et
al.,
2004)

Clinical
studyQuantita
tive
analysis

GFAP/
S100β

92

Blood
samplesa
monoclo
nal
immunol
uminome
tric assay
(LIAISO
N®
GFAP
and
S100β
assay,
AB
Sangtec
Medical,
Bromma,
Sweden)

S100β rose quicker and peaked
within the first 2 h, whereas
GFAP rose more steadily over
4 h and tapered slightly at 4 h.
Both GFAP and S100β were
related to brain damage, but
some (but not all) patterns of
TBI appeared to be associated
with differences between
GFAP and S100β release. Both
GFAP and S100β are good
predictors of mortality, and the
correlation between GFAP and
S100β release improves
with survival after TBI and is
strong beyond 36 h after
TBI.

CPP of 60
than CPP
of 60 mm
Hg
(p 0.0005)
MAP of
70 than
MAP of
70 mm Hg
(p
0.0005).
GFAP and
S100β
were
lower in
GOS 4–5
than in
GOS
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Author Type of BM
study/
Protein
Researc analyzed
h Design
(Theli
n et
al.,
2019)

Observa
tional
studyQuantita
tive
analysis

(S100β),
(NSE),
(GFAP),
(UCHL1), tau,
and
(NF-L

# Of
Participant
sExperime
nt/Control
172

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

Blood
samplesHuman
Neurolog
y 4-Plex
A assay
(N4PA)
on an
HD-1
Single
molecule
array
(Simoa)

In summary, a panel of several
different protein biomarkers,
all associated with injury
severity, with the different
cellular origin and temporal
trajectories, improve outcome
prediction models.

Media
n-55

NF-L:
8.8% at
103 pg/m
L 8.4% at
7.4 pg/mL

N/A

tau:
11.9% at
1.2 pg/mL
9.7% at
22.5 pg/m
L
GFAP:
9.0% at
72 pg/mL
7.3% at
88 pg/mL

(Janigr
o et
al.,
2020)

Pilot
StudyQuantita
tive
analysis

S100β

15/15

Saliva,
Serum
(Venous)
chemilu
minescen
ce and
automate
d
sandwich
ELISA
(LIAISO
N;
Diasorin,

The results have shown that:
(1) salivary levels of the
astrocytic protein S100β are
higher than those measured in
serum
(2) the diagnostic properties of
S100β in the blood are like
those in saliva
(3) a correlation exists between
salivary and blood levels of
S100β in control and post-TBI
conditions.
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47

UCH-L1:
33.3% at
11.4 pg/m
L 34.0%
at
10.8 pg/m
L
N/A

Below 0.02
ng/mL

Author Type of BM
study/
Protein
Researc analyzed
h Design

(Papa
et al.,
2016)

Prospect
ive
cohort
studyQuantita
tive
analysis

# Of
Participant
sExperime
nt/Control

GFAP
584
and
UCH-L1

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Stillwater
, MI)

A crucial aspect of TBI
diagnostics is the fact that
although serum markers such
as GFAP, UCH-L1, or S100β
already rule out clinically
important concussion sequelae
with an excellent negative
predictive value and a low
limit of detection in
laboratory-based approaches,
there is currently no translation
of this technology to a salivabased POI or POC device.
GFAP performed consistently
in detecting mTBI, CT lesions,
and neurosurgical intervention
across 7 days.

Blood
samplessandwich
enzymelinked
immunos
orbent
assays

UCH-L1 performed best in the
early post-injury period.

Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

40

GFAP
levels
Median:
0.112
ng/mL
IQR:
0.0300.462
ng/mL
Range:
0.0088.078
ng/mL

GFAP
levels
Median,
0.008
ng/mL
IQR,
0.0080.030
ng/mL
Range,
0.0080.773
ng/mL)
(P < .001).

UCH-L1
were
significant
ly higher
Median:
0.258
ng/mL
IQR:
0.1090.627
ng/mL
Range:
0.04521

UCH-L1
Median,
0.171
ng/mL
IQR,
0.1000.417
ng/mL
Range,
0.0454.241
ng/mL

Author Type of BM
study/
Protein
Researc analyzed
h Design

(Wolf
et al.,
2013)

(Romn
er et
al.,
2000)

Cohort
studyQuantita
tive
analysis

Clinical
studyQuantita
tive
analysis

S100β
and
(NSE)

S100β
protein

# Of
Participant
sExperime
nt/Control

114

278/110

Sampling
typeAssay
analyzer

Periphera
l venous
blood
samplessandwich
technique
with NSE
kits and
the
Elecsys
2010
analyzer
(Roche
Diagnosti
cs)
Blood
samplesimmunor
adiometri
c assay
kit
(detectio
n limit,
0.2 m
g/L.
Sangtec
Medical,
Bromma,
Sweden)

Results, Conclusion
And
Recommendations

The integration of the
biomarker panel as part of a
diagnostic rule including highrisk factors symptoms is safe
and reliable in determining a
diagnosis, pending the
availability of more brainspecific biomarkers.

S100β protein is established as
a serum marker of traumatic
brain injury. An undetectable
serum level of S100β protein
predicts normal intracranial
findings on a CT scan.
Determination of S100β
protein in serum may be used
to select patients for scanning
in situations where CT is in
short supply or where patients
need to be sent long distances
to obtain a CT.

Mean
age of
partici
pants

59 ±
23

BM levels
in TBI
patients

BM levels
in controls

9.000
ng/mL

(P < .001)

In patients N/A
with a
subarachn
oid
hemorrhag
e,
S100β
Median:
0.98 μg/L
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NSE
Median:
18.14
μg/L.
Patients
suffering
severe
head
injury had
detectable
S100β
levels
within
24 h
Postinjury.
Mean: 3.6
m g/L
Range:
1.2–12.5
m g/L
S100β was
detected in
75% of
moderate
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N/A

Author Type of BM
study/
Protein
Researc analyzed
h Design

(Lewis Clinical (GFAP)
et al., study - S100β,
2017) Quantita and
tive
(UCHanalysis L1)

(Bouvi
er et
al.,
2016)

Clinical
study Quantita
tive
analysis

S100β

# Of
Participant
sExperime
nt/Control

247/247

39/27

Sampling
typeAssay
analyzer

Results, Conclusion
And
Recommendations

Blood
sampleselectroch
emilumin
escence
immunoa
ssay
designed
for in
vitro
diagnosti
c testing
(Cobas
6000,
Roche),
enzymelinked
immunos
orbent
assay

A single serum concentration
of GFAP, UCH-L1, or S100β
within 6 hours of a head injury
may be useful in identifying
and stratifying the severity of
brain injury in emergency
department patients with head
trauma but cannot reliably
exclude a diagnosis of a
concussion.

Venous
blood
samplesserum
S100β
concentra
tions by
electrochemilu

S100β measured 36 h after a
match is thus a discriminating
test to identify concussion in a
male rugby player, with a 100
% negative predictive value.

Mean
age of
partici
pants

48.4

head
injuries
and 35%
of mild.
Mean: 0.7
m g/L
Range:
0.2–2.2
m g/L
GFAP
Median:
20.0
pg/mL
Range:
20.0–36.7
UCH-L1
Median:
64.0
pg/mL
Range:
30.0–
110.4

A positive GFAP was
associated with the presence of
concussion.
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BM levels
in TBI
patients

28.6

S100β
Median:
120.0
pg/mL
Range:
75.0–
240.0
The
median
basal
concentrat
ion over
the whole
season
was 0.05
lg/L

BM levels
in controls

S100β are
given in
μg/L
Standard
normal
reference
intervals:
0.00 to
0.09 μg/L.

N/A

Author Type of BM
study/
Protein
Researc analyzed
h Design

(Di
Battist
a et
al.,
2018)

Clinical
study Quantita
tive
analysis

# Of
Participant
sExperime
nt/Control

GFAP,
19/19
S100β,
NSE,
Totaltau
(NRGN)
,
(CKBB)
,
(VILIP)1,
(vWF),
(BDNF),
(PRDX)
-6, and
(MCP)1

Sampling
typeAssay
analyzer
minescen
ce
immunoa
ssay on a
Roche
Diagnosti
cs Cobas
e411
instrume
nt
(Meylan,
France)
Venous
blood
samples:
electroch
emilumin
escent
SULFOTagTM,
sensitive
electroch
emilumin
escence
detection
via
sandwich
immunoa
ssay

Results, Conclusion
And
Recommendations

Mean
age of
partici
pants

BM levels
in TBI
patients

BM levels
in controls

Minimum:
0.02,
Maximum
: 0.15
IQR:
0.04–0.06

Findings support the continued
application of blood
biomarkers to help elucidate
the pathophysiology of
secondary injury after SRC.
Higher circulating levels of
PRDX-6 in athletes with SRC
compared to control athletes in
the subacute phase after injury
and identified a relationship
between SRC and higher
PRDX-6 and T-tau levels at
medical clearance.
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PRDX-6
24.6 vs.
20.7
ng/mL
T-tau
20.4 vs.
14.4
pg/mL

Quality Score and Level of Evidence
The overall quality score did not vary for the articles, with 14 of the studies having a quality range
of between 8. Based on the Research and Quality Scoring Method, all the included studies were
considered high quality. The studies were rated according to their characteristics, and the score
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N/A

determines the reliability of their published findings. However, none of the studies performed
sample justification. (See quality Table 4)
Table 4: Quality Assessment Scoring
Quality Assessment

element of assessment

Study design

Outcome measure

Clarity of outcome
Information on withdrawal or
dropout rate
Research question
Participants in sample
Participant inclusion/ exclusion
criteria

scoring criteria
0 = Non-randomized, systematic review,
observational, cohort study
1 = Randomized experiment, quasiexperiment
0 = measure of the outcome is self report
1 =measure of the outcome been
mentioned using validated measure
0 = no definition of study outcome
1 = Clearly defined the study outcome
0 = not stated or discussed
1 = Clearly stated [number and reasons
0 = not clear
1 = Clearly stated
0 = not clear
1 = Clearly identified and described
0 = not clear

(Papa (Pelink (Thelin (Janigro (Papa et (Wolf (Romner (Lewis (Bouvie (Di Battista
et al., a et al., et al.,
et al.,
al.,
et al.,
et al.,
et al., r et al.,
et al.,
2014) 2004) 2019)
2020)
2016) 2013)
2000)
2017) 2016)
2018)

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

0

1

1

1

1

1

1

1

1

1

1

1

1

1

1

0

0

0

0

1
1
1
1

1 = specified
0 = not clear

Type of location where study
conducted and type of data
collection performed
Sample size justification and power
analysis

(Blais(Schulte (Bogoslov (HERRMA
L’Écuyer et et al., sky et al., NN et al.,
al., 2020)
2015)
2017)
2000)

1

1

1
1

1 = Clearly stated
0 = Unclear/not provided
1 = Sufficiently described and justified
before the study

Total
the score will be divided into 3 groups:
0 to 5
6 to 9

1
0

0

0

0

0

0

0

0

8

8

8

8

8

8

8

8

0

0
8

8

8

low quality
high quality

Biomarker Utility in Sport Setting
The review was carried out to determine the efficacy of biomarkers GFAP, S100β, Total-tau, and
NSE to aid the screening patients presenting with symptoms of mild traumatic brain injury (mTBI).
The focus is on athletes presenting at an emergency department with possible mTBI requiring a
CT scan based on the application of a clinical algorithm. The mentioned biofluid biomarkers have
a strong predictive ability for mTBI, and their use could reduce the number of CT scans among
athletic TBI patients. Athletes who play in higher divisions such as professional or collegiate often
sustain one or multiple concussions. The important things in this setting are to determine whether
a concussion has happened, and the level of injury sustained. It is possible to make real-time
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7

8

8

decisions regarding “return to play” decisions for athletes using a biomarker that is detected in
circulation within 30 minutes post-impact. [46] If they are tested again within days of a concussion,
combined with other measures such as the Glasgow coma scale (GCS), a scoring system used to
determine the level of consciousness post mTBI [23], they could be useful in “return to play”
decisions. A key characteristic of sports-related mTBI is repeated concussions over time, both in
a recreational and professional sports setting. The forest plot below shows the negative predictive
value of the four biomarkers.
Figure 2: Forrest Plot on predictive utility

Figure 2 categorizes selected quantitative articles. This allowed me to directly compare the
chosen studies and determine quality all in one platform. The studies had low heterogeneity or
variability (P<0.23) and the I2 statistic equaled 26%. A random-effects model was used to
estimate the mean of a distribution of effects. The weight (%) reflects how much of an impact a
study or subgroup had on the overall findings. The vertical line represents the null effect. The
horizontal lines on the plot represent the scale for statistics of Odds Ratio and the 95%
confidence intervals. The blue boxes located on the horizontal lines represent the estimate of the
study result. The smaller the blue box, the fewer participants in the study and vice versa. The
diamond located towards the bottom of the plot illustrates the point estimate and confidence
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intervals after the studies or subgroups were averaged. A test of heterogeneity is the I2 statistic.
The formula for calculating I2 from Cochran's Q is I2 = 100 percent X (Cochran's Q – degrees of
freedom). [50] The plot shows the odd ratios favor the control group thus depicting the negative
predictive value of the biomarkers such that in the control group no mTBI case was reported.
The biomarkers were only present in the experimental group which had cases of mTBI.
Biomarkers may be of considerable use in the management of SRC mild traumatic brain injury.
This figure was created using a 5.4 version of the Revman software.
Figure 3: Funnel Plot on the efficacy of biomarkers

Figure 3 also categorizes selected quantitative articles and assesses the potential role of
publication bias. This figure shows lower quadrant precision. The standard error of the effect
estimate was chosen as the measure of study size and plotted on the y-axis. This funnel plot
screened the distribution of 14 studies for negative predictive value according to the average shown
on the y-axis SE (log [OR]) and the mean result on the x-axis (OR). This plot depicted the
probability of biomarkers and assessment of publication bias. This figure was also created using a
5.4 version of the Revman software.
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DISCUSSION
From the review findings, it was established that the use of biofluid biomarkers in the prediction
of mild traumatic brain injury due to SRC is significant when the markers are used in large
combinations. Notably, Schulte et al. (2015) determined that NSE biomarkers, the reference
intervals that are being used, should not be applied to athletes. This discovery supports clinical
medicine and raises the bar for the development and implementation of population-specific
reference intervals. They establish that in the context of physical activity, provision of established
reference intervals can be difficult; therefore, strict control should be maintained during
experimental design determination. This tight control should also be carried over during sample
collection for studies and in the establishment of protocols for the implementation of biomarkers
in the diagnosis of mTBI, especially among athletes. Schulte et al. (2015), however, report that at
the time an athlete returns to play and at the end of the season the results for the given biomarkers
were 100% and within athlete reference intervals. According to Herrmann et al. (2000) the
considerable positive correlation between S100β and NSE concentrations and the number of
impacts in their study suggests there is a direct correlation between increased concentrations of the
proteins and traumatic brain injury. As such these proteins can be useful in the diagnosis of SRC
mild traumatic brain injury. Herrmann et al. (2000) also determine that the way NSE and S100β
are released can describe the pathophysiological impacts of brain injury and illustrate complex
neuronal-glial interactions.

S100β protein, according to Romner et al. (2000) has been use as a serum marker for traumatic
brain injury. Minute serum concentrations of S100β protein suggest normal intracranial results
from neurological imaging techniques such as CT and X-ray scans. Significant concentrations of
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the protein in serum can be used to inform the decision of which patients qualify for CT scans in
scenarios where the CT is not a viable option such as when patients must travel long distances to
obtain one. From their study, Bouvier et al. (2016) conclude that the S100β biomarker can be used
as a discriminating test to predict traumatic brain injury after thirty-six hours of impact. This test
provides a 100% negative predictive value. Blais-L’Écuyer et al. (2020) determine that S100β
serum protein concentration in blood serum samples is unrelated to clinically significant
intracranial hemorrhage in patients with mild traumatic brain injury. The protein biomarker was
also not effective and productive in reducing the number of patients prescribed with CT scans in
the emergency department. Significant traumatic brain injuries would have gone unaddressed if
this protein was solely used in the diagnosis of mTBI.

GFAP out-performed S100β in the prediction of traumatic CT lesions, especially in the context of
extracranial lesions on head scans and the extremities Papa et al., (2014). The two proteins were
detectable in blood serum, within the general trauma population after about an hour after impact
to the head. The temporal patterns of the two biomarkers, however, differed somewhat. S100β
protein concentration in the serum increased significantly and peaked within the preceding 2 hours
of injury while GFAP increased gradually and climaxed after about four hours. Pelinka et al.
(2004) findings support the conclusions arrived at by Papa et al. (2014), although some forms of
TBI were not associated with differences between the two biomarkers released. According to
Pelinka et al. (2004), GFAP and S100β are reliable predictors of mortality, and their correlation in
their release amends and strengthens after thirty-six hours. Papa et al. (2016) compared the
predictive utility of GFAP in diagnosing mild and moderate traumatic brain and determined that
the former effectively performed injury within seven days of injury while the utility of the latter
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became apparent in the very early post-injury period. According to Lewis et al. (2017), a single
blood test for the concentration of GFAP or S100β within 6 hours of a head impact may be useful
in predicting the severity of brain injury in patients with a head injury, but it cannot effectively
rule out a diagnosis of concussion.

The use of biomarkers in the prediction of mild traumatic brain injury is substantiated by the use
of multiple biomarkers such as in a panel. According to Thelin et al. (2019), a panel of several
different protein biomarkers, all related to the degree of injury, improve the results of prediction
models. These biomarkers usually have different cellular origins and temporal trajectories. The
implementations of such a panel, concurrently with observable high-risk factors symptoms,
provide a reliable protocol for diagnosing mTBI. Wolf et al. (2013). This is, however, a temporary
solution as research continues to identify more effective and conclusive biomarkers for diagnosis.

The pathophysiology of sports-related concussion can be clarified using biofluid biomarkers,
according to the findings of Di Battista et al. (2018). In the subacute phase after injury, significant
circulating levels of PRDX-6 are found in athletes with SRC. Furthermore, the high levels
identified a relationship between SRC and higher PRDX-6 and T-tau levels at medical clearance.
While there is not enough evidence to support the importance of tau biomarkers alone in the
management of patients with SR-TBI, understanding the relationship between PRDX-6 and tau,
suggests great potential for future research. Bogoslovsky et al. (2017) establish that plasma
biomarkers GFAP, tau, and Ab42, can be used in combination within the first thirty days of injury
to differentiate controls of complicated traumatic brain injury populations and can be reliable
predictors of TBI in both acute and subacute phases of injury. Janigro et al. (2020) determine that
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salivary concentration of astrocytic protein S100β are higher than those measured in serum after
head injury. S100β levels in saliva are similarly predictive to those in the blood, and there is a
correlation between the two. [49] However, currently, there exists no implementation of this
technology for saliva-based POI. [49] GFAP and S100β, biofluid biomarkers with an excellent
negative predictive value and a low limit of detection in laboratory-based approaches, tend to miss
clinically significant concussion sequelae.

Study Strengths and Limitations
Meanwhile, some limitations noted throughout this meta-analysis are to be discussed. The focus
of this meta-analysis was on the four most investigated biofluid biomarkers after mTBI, but other
biomarkers including neurofilament light protein (NF-L) were not included in this meta-analysis.
[16] In this meta-analysis, I looked specifically at biomarkers in SR-TBI. I omitted studies that
were not SR-TBI-specific and some of these studies showed biomarker levels to be significantly
correlated with TBI. The S100β biomarker levels in the blood are equivalent to those in the saliva,
and there is a link between salivary and blood S100β levels in the control and post-TBI conditions.
[49] However, no deployment of this technology to saliva-based POI currently exists for biofluid
protein biomarkers. [49] Furthermore, this meta-analysis did not conduct or implement any
detailed research into the evaluation of a mTBI using POI salivary tests for biofluid protein
biomarkers. The lack of description or the lack thereof of control groups in most of the studies,
questions the reliability of the findings of this meta-analysis. The following studies failed to
describe or did not include control groups in their research meaning that they are less effective,
and their findings require more careful considerations: [25], [41], [30], [38], [39], [44], [45].
Despite these limitations, the evaluated biofluid biomarkers confirmed some success in predicting
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positive intracranial lesions in CT scans after mTBI. Hence, these biomarkers may be reflective of
a brain injury. The forest plot showed the odds ratio favoring the control group thus depicting the
negative predictive value of the biomarkers such that in the control group no mTBI case was
reported. This analysis also confirmed that the utility of biomarkers in the management of SRC
mild traumatic brain injury is considerable.

Conclusions and Future Directions
When engaging in sports-related activities, most athletes tend to engage in physical touch, which
may sometimes expose them to the risk of getting internal brain injuries, commonly known as
Traumatic Brain Injury. It has become increasingly important to diagnose concussions as early as
possible, especially in athletes who participate in sports and who suffer concussions regularly.
Luckily, the research on TBI biomarkers is rapidly advancing, with data suggesting several
promising candidates. Should these biomarkers be better established clinically, they could easily
hold many important roles. It was established that the utility of biomarkers in the prediction of
mTBI is significant when the markers are used in large combinations. These biomarkers can
potentially aid in more accurate clinical decision-making by clarifying injury severity and
monitoring injury progression and recovery. Utilizing biomarkers can reduce the cost of
diagnosing mTBI, and athletes will be exposed to less radiation than with current imaging
techniques. Developing biomarkers and incorporating them into guidelines could help athletes who
participate in collision sports, which are commonly known for being at high-risk of repeated head
injuries, return to sports safely. Biomarkers can potentially be the solution for accurate
identification and treatment of Traumatic Brain Injuries. Regarding future reference in data
collection, an alternative measure to the funnel plot is recommended to be employed to improve
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future data collection, such as a forest plot, in which more significant conclusions were found
within this review. Although several biomarkers of brain injury have been identified, continued
research is required. Biofluid biomarkers, in combination with other clinical data, would maximize
the diagnostic accuracy for athletes who suffer a mTBI, but the methodological limitations are
evident in biomarker research. This results in the need for the clinical utility of biomarker use in
mTBI to be further explored.
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